European Commission Approves Mpox Vaccine for Children Aged 2-12
EU regulators approve Bavarian Nordic's mpox/smallpox vaccine for children aged 2 to under 12 years.
The European Commission has granted approval for Bavarian Nordic's mpox/smallpox vaccine to be used in children aged 2 to less than 12 years. The decision, announced on August 7, extends the vaccine's availability to a younger demographic, marking a significant step in pediatric protection against the virus.
This regulatory clearance allows healthcare providers across the European Union to administer the vaccine to children in this age group, broadening the scope of immunization efforts against mpox. The approval comes amid ongoing public health monitoring of the disease, which has seen outbreaks in various regions.
Bavarian Nordic, the Danish vaccine manufacturer, has not yet released detailed statements on the rollout or distribution plans for the pediatric population. The company's focus remains on ensuring the vaccine's safety and efficacy for this newly approved age bracket.
Public health authorities in EU member states will now determine how to integrate this pediatric indication into their national vaccination programs, potentially prioritizing children at higher risk of exposure. Further guidance from the company and regulatory bodies is expected in the coming weeks.